Peer-reviewedCC BYInternational journal of molecular sciences
Baseline Liver Metabolic Health in Newly Diagnosed People Living with HIV Compared with HIV-Negative Controls: Cross-Sectional Findings from the Prospective MASHIV-TR Cohort.
14 affiliations
- 1Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Dicle University, Diyarbakır 21280, Türkiye.
- 2Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Çukurova University, Adana 01330, Türkiye.
- 3Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Gaziantep University, Gaziantep 27310, Türkiye.
- 4Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University, İzmir 35100, Türkiye.
- 5Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara 06100, Türkiye.
- 6Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Akdeniz University, Antalya 07070, Türkiye.
- 7Department of Infectious Diseases and Clinical Microbiology, Prof. Dr. Cemil Taşçıoğlu City Hospital, University of Health Sciences Türkiye, İstanbul 34384, Türkiye.
- 8Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Kocaeli University, Kocaeli 41380, Türkiye.
- 9Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Harran University, Şanlıurfa 63300, Türkiye.
- 10Department of Internal Medicine, Division of General Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06100, Türkiye.
- 11Epidemiology Doctorate Program, Graduate School of Health Sciences, Istanbul Medipol University, İstanbul 34815, Türkiye.
- 12Department of Biostatistics and Medical Informatics, Faculty of Medicine, Dicle University, Diyarbakır 21280, Türkiye.
- 13Department of Infectious Diseases and Clinical Microbiology, Acıbadem Adana Hospital, Adana 01130, Türkiye.
- 14Department of Infectious Diseases and Clinical Microbiology, Güven Hospital, Ankara 06540, Türkiye.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important comorbidity in people living with HIV (PLWH), yet most data derive from individuals receiving antiretroviral therapy (ART). In the baseline cross-sectional analysis of the prospective multicentre MASHIV-TR cohort (nine centres, Türkiye), we compared 250 newly diagnosed, ART-naïve PLWH and 161 HIV-negative controls. Hepatic steatosis and liver stiffness were assessed by vibration-controlled transient elastography; MASLD was defined as hepatic steatosis, indicated by CAP ≥ 248 dB/m together with at least one cardiometabolic risk factor. MASLD prevalence was similar in the two groups (25.2% vs. 30.4%; p = 0.245), and HIV status was not independently associated with MASLD. Triglyceride level was independently associated with CAP in PLWH (+10.69 dB/m per 50 mg/dL) and in controls (+9.26 dB/m), whereas CD4 and CD8 counts, the CD4/CD8 ratio and HIV-RNA were not associated with the liver outcomes. Before ART, hepatic steatosis tracked metabolic rather than HIV-specific markers.
Related
- Effectiveness of metformin as initial treatment on the metabolic profile of Saudi patients newly diagnosed with type 2 diabetes mellitus : A prospective observational study
- Additive interaction between ultrasound-diagnosed metabolic dysfunction-associated steatotic liver disease and hyperuricemia on impaired fasting glucose: a large-scale cross-sectional study
- Associations of baseline levels, cumulative exposure, and two-wave patterns of the combined triglyceride-glucose index and frailty index with progression from cardiovascular-kidney-metabolic syndrome stages 0-2 to stages 3-4 and stage 4: a prospective cohort study from CHARLS.
- Metabolic syndrome in patients diagnosed with affective disorders: a cross-sectional study among inpatients from two Cluj-Napoca psychiatry clinics
- Coexistence of microvascular complications in type 2 diabetes: a baseline cross-sectional analysis of the Japan Diabetes Complication and its Prevention prospective study (JDCP study 13)
BibTeX
@article{mermutluoglu2026baseline,
title = {{Baseline Liver Metabolic Health in Newly Diagnosed People Living with HIV Compared with HIV-Negative Controls: Cross-Sectional Findings from the Prospective MASHIV-TR Cohort.}},
author = {Çiğdem Mermutluoğlu and Yeşim Taşova and Ayşe Özlem Mete and İlkay Karaoğlan and Hüsnü Pullukçu and Meliha Çağla Sönmezer and Dilara İnan and Funda Şimşek and Sıla Akhan and Tuba Damar Çakırca and Nursel Çalık Başaran and Aslıhan Candevir and Yeliz Çiçek and Damla Ertürk and Ahmet Çağkan İnkaya and İsmail Yıldız and Behice Kurtaran and Müge Toygar Deniz and Yaşar Bayındır and Mustafa Kemal Çelen},
journal = {International journal of molecular sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198672},
url = {https://europepmc.org/article/MED/42883917},
note = {CC BY},
}
RIS
TY - JOUR
TI - Baseline Liver Metabolic Health in Newly Diagnosed People Living with HIV Compared with HIV-Negative Controls: Cross-Sectional Findings from the Prospective MASHIV-TR Cohort.
AU - Çiğdem Mermutluoğlu
AU - Yeşim Taşova
AU - Ayşe Özlem Mete
AU - İlkay Karaoğlan
AU - Hüsnü Pullukçu
AU - Meliha Çağla Sönmezer
AU - Dilara İnan
AU - Funda Şimşek
AU - Sıla Akhan
AU - Tuba Damar Çakırca
AU - Nursel Çalık Başaran
AU - Aslıhan Candevir
AU - Yeliz Çiçek
AU - Damla Ertürk
AU - Ahmet Çağkan İnkaya
AU - İsmail Yıldız
AU - Behice Kurtaran
AU - Müge Toygar Deniz
AU - Yaşar Bayındır
AU - Mustafa Kemal Çelen
PY - 2026
DA - 2026/09/28
JO - International journal of molecular sciences
DO - 10.3390/ijms27198672
UR - https://europepmc.org/article/MED/42883917
AB - Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important comorbidity in people living with HIV (PLWH), yet most data derive from individuals receiving antiretroviral therapy (ART). In the baseline cross-sectional analysis of the prospective multicentre MASHIV-TR cohort (nine centres, Türkiye), we compared 250 newly diagnosed, ART-naïve PLWH and 161 HIV-negative controls. Hepatic steatosis and liver stiffness were assessed by vibration-controlled transient elastography; MASLD was defined as hepatic steatosis, indicated by CAP ≥ 248 dB/m together with at least one cardiometabolic risk factor. MASLD prevalence was similar in the two groups (25.2% vs. 30.4%; p = 0.245), and HIV status was not independently associated with MASLD. Triglyceride level was independently associated with CAP in PLWH (+10.69 dB/m per 50 mg/dL) and in controls (+9.26 dB/m), whereas CD4 and CD8 counts, the CD4/CD8 ratio and HIV-RNA were not associated with the liver outcomes. Before ART, hepatic steatosis tracked metabolic rather than HIV-specific markers.
SN - 1422-0067
ER -